疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2015年
9期
910-912,913
,共4页
伉奕%马宇%黄莹%展群岭
伉奕%馬宇%黃瑩%展群嶺
항혁%마우%황형%전군령
瑞舒伐他汀钙%短暂性脑缺血%颈动脉斑块%血脂
瑞舒伐他汀鈣%短暫性腦缺血%頸動脈斑塊%血脂
서서벌타정개%단잠성뇌결혈%경동맥반괴%혈지
Rosuvastatin calcium%Transient cerebral ischemia%Carotid plaque%Blood lipid
目的:观察瑞舒伐他汀钙辅治短暂性脑缺血发作(TIA)患者对颈动脉斑块和血脂的影响。方法选取TIA患者76例为研究对象,按随机数字表法分为治疗组39例和对照组37例。对照组给予尼莫地平、阿司匹林、胞二磷胆碱、低分子右旋糖酐等常规药物治疗,治疗组在对照组治疗基础上给予瑞舒伐他汀钙10 mg/d,连续服用6个月。治疗前后分别行颈动脉粥样硬化斑块、血脂检测;随访6个月,分别记录脑血管疾病发生情况及不良反应。结果治疗后治疗组颈动脉内膜中层厚度( IMT)明显变薄,斑块面积显著缩小,TC、TG、LDL-C水平较治疗前明显下降(P﹤0.05),HDL-C无统计学意义( P <0.05);对照组治疗前后上述指标均无显著变化,差异无统计学意义( P >0.05);2组治疗后,颈动脉内膜和斑块面积、TC、TG、LDL-C水平比较差异均有统计学意义( P <0.05)。治疗组脑血管疾病发生率(10.3%)明显低于对照组(21.6%)(χ2=4.762, P <0.05),2组患者治疗期间均未发生严重不良反应。结论瑞舒伐他汀钙辅治能有效减轻颈动脉粥样硬化斑块,降低血脂水平和脑血管疾病事件的发生率,值得临床应用推广。
目的:觀察瑞舒伐他汀鈣輔治短暫性腦缺血髮作(TIA)患者對頸動脈斑塊和血脂的影響。方法選取TIA患者76例為研究對象,按隨機數字錶法分為治療組39例和對照組37例。對照組給予尼莫地平、阿司匹林、胞二燐膽堿、低分子右鏇糖酐等常規藥物治療,治療組在對照組治療基礎上給予瑞舒伐他汀鈣10 mg/d,連續服用6箇月。治療前後分彆行頸動脈粥樣硬化斑塊、血脂檢測;隨訪6箇月,分彆記錄腦血管疾病髮生情況及不良反應。結果治療後治療組頸動脈內膜中層厚度( IMT)明顯變薄,斑塊麵積顯著縮小,TC、TG、LDL-C水平較治療前明顯下降(P﹤0.05),HDL-C無統計學意義( P <0.05);對照組治療前後上述指標均無顯著變化,差異無統計學意義( P >0.05);2組治療後,頸動脈內膜和斑塊麵積、TC、TG、LDL-C水平比較差異均有統計學意義( P <0.05)。治療組腦血管疾病髮生率(10.3%)明顯低于對照組(21.6%)(χ2=4.762, P <0.05),2組患者治療期間均未髮生嚴重不良反應。結論瑞舒伐他汀鈣輔治能有效減輕頸動脈粥樣硬化斑塊,降低血脂水平和腦血管疾病事件的髮生率,值得臨床應用推廣。
목적:관찰서서벌타정개보치단잠성뇌결혈발작(TIA)환자대경동맥반괴화혈지적영향。방법선취TIA환자76례위연구대상,안수궤수자표법분위치료조39례화대조조37례。대조조급여니막지평、아사필림、포이린담감、저분자우선당항등상규약물치료,치료조재대조조치료기출상급여서서벌타정개10 mg/d,련속복용6개월。치료전후분별행경동맥죽양경화반괴、혈지검측;수방6개월,분별기록뇌혈관질병발생정황급불량반응。결과치료후치료조경동맥내막중층후도( IMT)명현변박,반괴면적현저축소,TC、TG、LDL-C수평교치료전명현하강(P﹤0.05),HDL-C무통계학의의( P <0.05);대조조치료전후상술지표균무현저변화,차이무통계학의의( P >0.05);2조치료후,경동맥내막화반괴면적、TC、TG、LDL-C수평비교차이균유통계학의의( P <0.05)。치료조뇌혈관질병발생솔(10.3%)명현저우대조조(21.6%)(χ2=4.762, P <0.05),2조환자치료기간균미발생엄중불량반응。결론서서벌타정개보치능유효감경경동맥죽양경화반괴,강저혈지수평화뇌혈관질병사건적발생솔,치득림상응용추엄。
Objective To observe the effect of atorvastatin calcium on carotid plaque and blood lipid in patients with transient ischemic attack ( TIA) .Methods Selected 76 TIA patients as the research object , according to the random number table, they were divided into treatment group with 39 cases and control group with 37 cases.The control group was given ni-modipine and aspirin , cell diphosphate choline , low molecular weight dextran and conventional drug therapy , based on the above treatment, the treatment group also given rosuvastatin calcium 10 mg/d, for taking six months.Carotid atherosclerosis plaque and blood lipid were detected before and after treatment .The incidence and adverse reactions of cerebrovascular disea-ses were recorded after 6 months of follow-up.Results After treatment, treatment group’s carotid artery intima-media thick-ness ( IMT) became thin, plaque area was significantly reduced , TC, TG, LDL-C levels decreased obviously than before treatment ( t =3.062, t =3.641, t =3.016, t =4.019, t =2.943, P <0.05), HDL-C have no statistically significant (t =1.951, P <0.05), and in the control group before and after treatment , the index had no significant change , the differ-ence was not statistically significant ( t =0.401, t =1.009, t =0.941, t =1.038, t =1.131, t =0.491, P >0.05).In the treatment group , the carotid artery intima and plaque area , TC, TG, LDL-C level differences were statistically significant ( P <0.05).In treatment group, cerebral blood vessel disease incidence rate (10.3%) was significantly lower than that of the control group (21.6%) (χ2 =4.762, P <0.05).During the treatment, the patients in both of the two groups did not oc-cur serious adverse reactions .Conclusion Rosuvastatin calcium assisted treatment can effectively reduce the carotid athero-sclerosis plaque , reduce the incidence of blood lipid level and cerebrovascular events , it is worthy of clinical application .